LEO Pharma is a global pharmaceutical company headquartered in Denmark. Founded in 1908, it has grown to become a leading player in the dermatology and critical care fields. LEO Pharma's headquarters is located in Ballerup, Denmark.

The company has a strong presence in more than 100 countries, with production facilities in Denmark, France, and Ireland. The company offers a wide range of products and services. Its dermatology portfolio includes treatments for psoriasis, eczema, and other skin conditions.

LEO Pharma is known for its innovative topical medications and biologics, which help alleviate symptoms and improve the quality of life for patients. In the critical care field, the company specializes in developing and manufacturing medications for the hospital setting, focusing on conditions such as thrombosis and coagulation disorders. LEO Pharma has several noteworthy subsidiaries, joint ventures, and partnerships.

One of its subsidiaries is LEO Pharma Inc., located in the United States, which focuses on providing innovative treatments to the American market. In 2019, LEO Pharma entered into a strategic partnership with PellePharm, a biotech company specializing in rare genetic skin diseases. This partnership allows LEO Pharma to expand its presence in the rare diseases space.

In terms of market position, LEO Pharma is recognized as a global leader in dermatology. With annual sales exceeding EUR 1 billion, the company holds a strong position among its competitors. It has a dedicated sales force to market its products and works closely with healthcare professionals to ensure patients receive optimal care.

LEO Pharma has had several major achievements and strategic changes in recent years. In 2017, the company launched a new innovation unit called LEO Pharma A/S Bio Derm, aimed at developing new treatment options for dermatological conditions. Additionally, the company has made investments in research and development to expand its pipeline of potential medications.

As of the latest updates, LEO Pharma continues to focus on advancing its mission of helping people achieve healthy skin. The company remains committed to innovation and collaborating with partners to develop new therapies. It continuously strives to improve the lives of people suffering from dermatological and critical care conditions.

In conclusion, LEO Pharma is a globally recognized pharmaceutical company known for its expertise in dermatology and critical care. With a strong market presence, extensive product range, and emphasis on innovation, the company plays a significant role in improving the lives of patients worldwide